Skip to main content

BioCommunique Article

Bringing you the latest financial and strategic news from top leaders in life science over the past two weeks.

GSK Invests $67M to Co-Found Genomics Lab, NuVasive LessRay® Platform Wins Gold, Oncternal Goes Public

  • 2019-06-13T21:19:00.000+0000
  • California
  • Author: Lauren Panetta

6/13/19 – Endpoints
GSK's Barron joins hands with Doudna, Weissman to deploy CRISPR tech in drug discovery

6/13/19 – Endpoints
AbbVie touts new data for Humira successor; Gilead inks discovery deal

6/13/19 – BioSpace
GSK Invests $67 Million to Co-Found Genomics Lab with University of California

6/13/19 – FierceBiotech
Pfizer's Xeljanz matches immunosuppressant combo in rheumatoid arthritis study

6/13/19 – BioPharma Dive
Moody's: Amgen, Biogen, Gilead have 'high capacity' to do M&A

6/13/19 – FierceBiotech
Terumo plans to take Orchestra BioMed's sirolimus balloon international in $35M deal

6/13/19 – BioSpace
Genentech’s Rituxan Superior in Rare, Deadly Skin Disease

6/12/19 – GEN
Janssen, Genmab Partner on Follow-On to Darzalex for Multiple Myeloma, Diffuse Large B-Cell Lymphoma

6/12/19 – BioSpace
NuVasive LessRay® Platform Wins Gold at 2019 Medical Design Excellence Awards

6/12/19 – Xconomy
Oncternal Therapeutics Goes Public After Reverse Merger With GTx

6/12/19 – BioSpace
Invitae Announces ID YOUR IRD Program to Expand Access to Genetic Testing for Inherited Retinal Disorders

6/11/19 – San Diego Union-Tribune
Mapp Biopharmaceutical gets up to $46.5 million for new viral disease drug

6/11/19 – FierceBiotech
Novo Nordisk's oral semaglutide posts another heart safety win

6/11/19 – FierceBiotech
Eli Lilly's Taltz seeking an edge with long-term clear skin data

6/10/19 – FiercePharma
Sanofi launches patient-centric diabetes campaign

6/7/19 – FierceBiotech
Vertex makes $420M preclinical play for DMD gene editing field

6/6/19 – FierceBiotech
Thermo Fisher picks up mass spec software developer HighChem

6/5/19 – FierceBiotech
Amgen, Takeda join intracellular delivery R&D collaboration

6/4/19 – San Diego Union-Tribune
Cancer drug developer Inhibrx files for IPO

6/4/19 – FierceBiotech
Bayer inks Arvinas deal to develop protein degraders